These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 17484926

  • 1. Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcome.
    Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP.
    Urol Clin North Am; 2007 May; 34(2):219-25; abstract ix-x. PubMed ID: 17484926
    [Abstract] [Full Text] [Related]

  • 2. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
    Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP.
    J Clin Oncol; 2005 Sep 01; 23(25):6149-56. PubMed ID: 16135481
    [Abstract] [Full Text] [Related]

  • 3. Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer.
    Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP.
    Urol Oncol; 2005 Sep 01; 23(6):423-30. PubMed ID: 16301122
    [Abstract] [Full Text] [Related]

  • 4. Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome.
    Ong TA, Winkler MH, Savage PM, Seckl MJ, Christmas TJ.
    BJU Int; 2008 Jul 01; 102(2):198-202. PubMed ID: 18294302
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
    Beck SD, Patel MI, Sheinfeld J.
    J Urol; 2004 Jan 01; 171(1):168-71. PubMed ID: 14665869
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant chemotherapy for stage II nonseminomatous germ cell tumors.
    Kondagunta GV, Motzer RJ.
    Urol Clin North Am; 2007 May 01; 34(2):179-85; abstract ix. PubMed ID: 17484923
    [Abstract] [Full Text] [Related]

  • 10. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
    Willis SF, Winkler M, Savage P, Seckl MJ, Christmas TJ.
    BJU Int; 2007 Oct 01; 100(4):809-12. PubMed ID: 17711512
    [Abstract] [Full Text] [Related]

  • 11. Contemporary management of postchemotherapy testis cancer.
    Daneshmand S, Albers P, Fosså SD, Heidenreich A, Kollmannsberger C, Krege S, Nichols C, Oldenburg J, Wood L.
    Eur Urol; 2012 Nov 01; 62(5):867-76. PubMed ID: 22938868
    [Abstract] [Full Text] [Related]

  • 12. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer.
    Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL.
    Cancer; 2006 Oct 01; 107(7):1483-90. PubMed ID: 16944541
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
    Stephenson AJ, Bosl GJ, Motzer RJ, Bajorin DF, Stasi JP, Sheinfeld J.
    J Clin Oncol; 2007 Dec 10; 25(35):5597-602. PubMed ID: 18065732
    [Abstract] [Full Text] [Related]

  • 15. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
    Dash A, Carver BS, Stasi J, Bajorin DF, Motzer RJ, Bosl GJ, Sheinfeld J.
    Cancer; 2008 Feb 15; 112(4):800-5. PubMed ID: 18172902
    [Abstract] [Full Text] [Related]

  • 16. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
    Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ, Sheinfeld J.
    J Clin Oncol; 2007 Oct 01; 25(28):4365-9. PubMed ID: 17906201
    [Abstract] [Full Text] [Related]

  • 17. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
    Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J.
    J Clin Oncol; 2005 Apr 20; 23(12):2781-8. PubMed ID: 15837993
    [Abstract] [Full Text] [Related]

  • 18. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
    Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J.
    J Clin Oncol; 2007 Mar 20; 25(9):1033-7. PubMed ID: 17261854
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T, Kamoto T, Hara I, Kawai K, Nakao M, Nonomura N, Kobayashi T, Ogawa O, Kamidono S, Akaza H, Okuyama A, Kato T, Miki T.
    Cancer; 2003 Oct 15; 98(8):1635-42. PubMed ID: 14534879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.